The Science Journal of the American Association for Respiratory Care

1996 OPEN FORUM Abstracts

EFFECT OF FLUTTER DEVICE ON PULMONARY FUNCTION AMONG THE PEDIATRIC CYSTIC FIBROSIS POPULATION.

Dawn M. Geouque, RRT, Matthew Engelhardt, CRTT, RPFT, Alfred I, duPont Institute. Thomas Jefferson Medical University, Wilmington. DE 19899.

Previous studies have shown that the Scandiphram Flutter^{TM} airway cleara nce device has increassed the ability for cystic fibrosis patients to expectorate mucus. However, studies to show the effect of the Flutter device on pulmonary function among the pediatric cystic fibrosis patients are limited. Methods: The long term effect of the Flutter^{TM} device on Pulmonary Function Tests (PFTs) compared to other airway clearance techniques such as Chest Physiotherapy (CPT) and Vital Signs Inc. 9000PEEP^{TM} Positive Expiratory Pressure (PEP) therapy, were studied among 15 cystic fibrosis patients ages 5-17 with mild to moderate disease. Of the 15 patients that qualified for the study, 5 were excluded due to hospital admission for acute pulmonary exacerbation, 4 withdrew themselves from the study and 6 continued through the study. Each patient served as their own control throughout the study. The patients were evaluated using MedGraphics 1085D Body Plethsmograph Unit and Pf/Dx Pulmonary Function System^{TM} (PFTs) at the beginning and end of each new therapy. The duration of each therapy was 1 month. Along with each PFT a respiratory assessment was obtained which included: Respiratory rate, oxygen saturation, productive versus nonproductive cough, medications, breath sounds and general comments. Results: Overall, none of the respiratory assessment parameters changed between the therapies studied. All patients that used the Flutter device preferred it over the other 2 therapies. The patients stated they felt clinically better, were able to expectorate more mucuseasier and felt more in control of their therpaies. Pair-T Test statistical analysis from the PFT data, indicated no significant changes in FEV1, FEF25-75, Raw or aGaw among the 3 therapies studied

PARAMETER FEV1 FEF25-75 RaW sGaw

MEAN STDV:CPT 5.6 28.7 27.6 46.8

AVG % CHG:CPT 6.25 18.28 -12.95 26.89

MEAN STDV:PEP 5.2 23.1 27.9 43.2

AVG % CHG:PEP 7.74 31.68 -17.81 24.08

MEAN STDV:FLUT 9.6 20.9 26.9 21.7

AVG % CHG:FLUT 3.66 11.61 11.3 -8.25

(See original for figure)

CONCLUSION: Although previous studies have shown an increase amount of mucus expectoration using the Flutter device, this study has shown no significant change in respiratory assessment parameters or pulmonary function over the course of the study. Further studies are warranted involving multicenter trials to evaluate the effects of the Flutter device on pulmonary function.

Reference: OF-96-175

You are here: RCJournal.com » Past OPEN FORUM Abstracts » 1996 Abstracts » EFFECT OF FLUTTER DEVICE ON PULMONARY FUNCTION AMONG THE PEDIATRIC CYSTIC FIBROSIS POPULATION.